{"id":"irbesartan-amlodipine-low","safety":{"commonSideEffects":[{"rate":null,"effect":"Peripheral edema"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Hyperkalemia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Irbesartan is an angiotensin II receptor blocker (ARB) that prevents angiotensin II from constricting blood vessels, while amlodipine is a dihydropyridine calcium channel blocker that relaxes vascular smooth muscle by blocking calcium influx. Together, these complementary mechanisms provide synergistic antihypertensive effects with improved efficacy compared to monotherapy.","oneSentence":"This combination drug lowers blood pressure by blocking angiotensin II receptors (irbesartan) and calcium channels (amlodipine) to reduce vascular resistance and improve blood flow.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:17:09.145Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypertension"}]},"trialDetails":[{"nctId":"NCT05476354","phase":"PHASE3","title":"Clinical Efficacy and Safety Evaluation of Irbesartan and Amlodipine Combined Therapy in Essential Hypertension Patients","status":"COMPLETED","sponsor":"Handok Inc.","startDate":"2022-07-05","conditions":"Essential Hypertension","enrollment":271},{"nctId":"NCT05377203","phase":"PHASE4","title":"Low-dose Quadruple Combination Therapy in Patients With Hypertension","status":"COMPLETED","sponsor":"The Third Xiangya Hospital of Central South University","startDate":"2022-07-13","conditions":"Hypertension, Arterial Hypertension","enrollment":90},{"nctId":"NCT04488978","phase":"PHASE2","title":"Phase 2 Study to Evaluate the Efficacy and Safety of Irbesartan and Amlodipine Combined or Alone in Patients With Essential Hypetension","status":"COMPLETED","sponsor":"Handok Inc.","startDate":"2020-05-21","conditions":"Essential Hypertension","enrollment":440}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Irbesartan/Amlodipine low","genericName":"Irbesartan/Amlodipine low","companyName":"Handok Inc.","companyId":"handok-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination drug lowers blood pressure by blocking angiotensin II receptors (irbesartan) and calcium channels (amlodipine) to reduce vascular resistance and improve blood flow. Used for Hypertension.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}